Giardiasis

Summary

Giardiasis (MONDO:0001103) is a disease and 6 clinical trials. Top therapeutic interventions include auranofin, metronidazole, and tinidazole. A subtype of protozoa infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	giardiasis
Mondo ID	MONDO:0001103
MeSH	D005873
DOID	DOID:10718
ICD-10-CM	A07.1
ICD-11	433310499
SNOMED CT	10679007
UMLS	C0017536
MedGen	42213
Is cancer (heuristic)	no

Also known as: Giardia infection · Giardiases · infections, Giardia · Lambliases · lambliasis

Disease family

This is a subtype of protozoa infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › giardiasis

Related subtypes (14): primary amebic meningoencephalitis, granulomatous amebic encephalitis, trypanosomiasis, protozoal dysentery, trichomoniasis, malaria, Acanthamoeba keratitis, amebiasis, babesiosis, balantidiasis, coccidiosis, theileriasis, leishmaniasis, dientamoebiasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Metronidazole.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02942485	PHASE4	TERMINATED	Treatment of Giardia Lamblia Infections in Children
NCT02736968	PHASE2	COMPLETED	Auranofin for Giardia Protozoa
NCT07358910	Not specified	RECRUITING	Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
NCT00001162	Not specified	TERMINATED	Parasitic Infections of the Gastrointestinal Tract
NCT00607074	Not specified	COMPLETED	Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh
NCT02105714	Not specified	COMPLETED	Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AURANOFIN	4	1
METRONIDAZOLE	4	1
TINIDAZOLE	4	1
CHEMBL3774645	0	1
CHEMBL4303702	0	1
CHEMBL5279950	0	1